SKYE — Skye Bioscience Balance Sheet
0.000.00%
- $224.82m
- $145.28m
- 37
- 21
- 89
- 47
Annual balance sheet for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 1.83 | 2.47 | 8.98 | 1.24 | 1.43 |
Net Total Receivables | — | — | — | — | 0.032 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.99 | 2.66 | 9.61 | 8.94 | 11.7 |
Net Property, Plant And Equipment | 0.002 | 0.007 | 0.235 | 0.159 | 0.281 |
Other Long Term Assets | |||||
Total Assets | 2 | 2.67 | 9.86 | 9.11 | 11.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.971 | 0.787 | 3.91 | 12.1 | 13.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.45 | 2.22 | 3.99 | 12.1 | 14.1 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.548 | 0.451 | 5.86 | -3.01 | -2.13 |
Total Liabilities & Shareholders' Equity | 2 | 2.67 | 9.86 | 9.11 | 11.9 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |